Breaking Health News: Investment Moves, Drug Updates and Disease Outbreaks
This summary covers recent health events including investment in German firm Gerresheimer, updates on the U.S. Medicare drug list, Illumina's launch of gene sequencers, Baxter's IV supply restoration, FTC legal actions, and new authorizations and settlements from Novavax and GSK. Additionally, reports include Roche’s cancer drug trials and California's bird flu cases.

In a striking twist for German medical packaging maker Gerresheimer, shares soared nearly 6.8% on news that activist investor Ricky Sandler acquired a 5.43% stake. As markets responded, shares maintained a 4% increase on Wednesday post-disclosure.
The U.S. government has revealed a preliminary listing of 101 generic drugs capped at $2 for Medicare enrollees. This move marks a substantial step in reducing prescription costs, covering commonly used medications like penicillin and metformin.
Tech advancements continue as Illumina launches cost-effective gene sequencing devices, aiming to broaden access for research labs. Meanwhile, California confirms a third human bird flu case, raising concerns amid ongoing disease monitoring.
(With inputs from agencies.)
ALSO READ
First Human Case of Bird Flu Confirmed in Nevada Farm Worker
Communication Breakdown: The WHO's Bird Flu Challenges
Communication Breakdown: Bird Flu Messaging Amid U.S. Policy Shifts
Challenges in Bird Flu Communication Amidst U.S. Withdrawal from WHO
Nevada Dairy Worker Contracts New Bird Flu Strain